Neurol. praxi. 2011;12(1):33-36
New in pharmacotherapy of dementia
- 1 Neurologická klinika LF UK a FN Hradec Králové
- 2 Psychiatrická klinika LF UK a FN Hradec Králové
There has been only symptomatic treatment focused on amelioration of cognitive and behavioural symptoms. Acetylcholinesterase
inhibitors and N-acetyl-M-aspartate antagonist are currently the standard treatment in the most frequent dementia, Alzheimer’s disease.
In clinical practice, there is a tendency to broaden the spectrum of indications in present drugs, including the treatment of early
dementia stages or the treatment of different types of dementia. Simultaneously, new drug forms are tested. Regarding the research
area, multiple of brand new drug molecules reached the clinical phase. In some of them, causal influence on the Alzheimer’s dementia
is expected. We mention the most important of those molecules in our article.
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitor, memantin, amyloid-beta
Published: February 18, 2011 Show citation
References
- Burns A, O'Brien J, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, et al. on behalf of the BAP Dementia Consensus Group and British Assiciation for Psychopharmacotherapy. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharm 2006; 20: 732-755.
Go to original source... 
Go to PubMed... - Boada M, Ortiz P, Anaya F, Hernández I, Mu?oz J, Nú?ez L, Olazarán J, Roca I, Cuberas G, Tárraga L, Buendia M, Pla RP, Ferrer I, Páez A. Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 2009; 22: 325-339. Go to original source... Go to PubMed...
- Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J. Memapsin 2 (beta-secretase) inhibitors: dug development. Curr Alzheimer Res 2008; 5: 121-131. Go to original source... Go to PubMed...
- Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Tarenflubril Phase 3 Study Group. Effect of Tarenflubril on cognitive decline and activities of daily living in patients with mild Alzheimer disease. JAMA 2009; 302: 2557-2564. Go to original source... Go to PubMed...
- Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal J, Zotova E, and Nicholl JAR. Long-term effects of A-beta42 immunization in Alzheimer's disease: Follow-up of a randomized, placebo-controlled Phase 1 trial. Lancet 2008; 372(9634): 216-223. Go to original source... Go to PubMed...
- Hussain HM, Zakria M, Arshad AR. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008; 71: 2019-2020. Go to original source... Go to PubMed...
- Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St GeorgeHyslop P, Westaway D. A ?-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982. Go to original source... Go to PubMed...
- Jirak R. A new advancements in the biological therapy of dementias. Psychiat pro praxi 2010; 11: 143-144.
- Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials, BMJ 2005; 331: 321-327. Go to original source... Go to PubMed...
- Kirsch C, Eckert GP, Koudinov AR, Müller WE. Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 2003; 36(Suppl 2): S113-S119. Go to original source... Go to PubMed...
- Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta imunotherapy? Nat Rev Neurol 2010; 6: 108-119. Go to original source... Go to PubMed...
- Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A ?-peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985. Go to original source... Go to PubMed...
- National Institute for Health and Clinical Excellence, NICE clinical guideline 42, Dementia November 2006.
- Pogacic V, Herrling P. List of drugs in development for neurodegenerative diseases. Neurodegener Dis 2007; 4: 443-486. Go to original source... Go to PubMed...
- Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994; 27: 32-40. Go to original source... Go to PubMed...
- Sampaio C. Alzheimer's disease: disease modifying trials. Where are we? Where do we need to go? A reflective paper. J Nutr Health Aging 2006; 10: 113-115.
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177. Go to original source... Go to PubMed...
- Schneck MJ. Vascular dementia. Top Stroke Rehabil 2008; 15: 22-26. Go to original source... Go to PubMed...
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil, JAMA 2004; 291: 317-324. Go to original source... Go to PubMed...
- Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT. The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron-Responsive Element in the APPmRNA 5'-Untranslated Region. Ann N York Acad Sci 2004; 1035: 34-48. Go to original source... Go to PubMed...
- Whitehouse PJ. The Myth of Alzheimer's. St. Martin's Press, 2008.